BioMarin Pharmaceutical | BMRN - Ebitda


BioMarin Pharmaceutical reported $295.45M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Bayer EUR 1.51B 1.28B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Insmed USD -297.13M 71.11M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
PTC Therapeutics USD -33.11M 1B Jun/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 5.66B 3.77B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025